Why the study?
Mutations in desmoplakin (DSP) are associated with arrhythmogenic cardiomyopathy, an inheritable heart disease characterized by lethal heart rhythms and abnormal contractile function.
Key points are not available for this paper at this time.
Design
In vitro human induced pluripotent stem cell line generation study
No immediate clinical impact in arrhythmogenic cardiomyopathy; leaves open DSP-mutant hiPSC utility for disease modeling.
Arrhythmogenic cardiomyopathy is an inheritable heart disease characterized by lethal heart rhythms and abnormal contractile function. Mutations in desmoplakin (DSP), a protein linking the cardiac desmosome with intermediate filaments, are associated with arrhythmogenic cardiomyopathy. Here we generated a human induced pluripotent stem cell (hiPSC) line from a patient with a heterozygous protein-truncating variant in DSP (c.1386del Leu462Serfs*22). This line has a normal karyotype and expression of pluripotency markers, and can differentiate into all three germ layers. This line is well suited for in vitro mechanistic studies of mechanism of DSP protein-truncation mutations in the context of arrhythmogenic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Loiben et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: